Literature DB >> 18562052

Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population.

Amanda J Leach1, Peter S Morris, Grant Mackenzie, Joseph McDonnell, Anne Balloch, Jonathan Carapetis, Mimi Tang.   

Abstract

BACKGROUND: A unique schedule of 7-valent pneumococcal conjugate vaccine (7PCV) at 2, 4 and 6 months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months commenced for Australian Aboriginal infants in 2001.
METHODS: Anti-capsular IgG concentrations in vaccinated and non-vaccinated (historic control) infants were determined (blinded) by (22F absorbed) ELISA.
RESULTS: One month after dose 3 of 7PCV, geometric mean concentrations (GMCs) were >1.95 microg/ml and at least 89% of infants had IgG >0.35 microg/ml to all 7PCV serotypes. One month post-23PPV, IgG to 7PCV serotypes was >0.35 microg/ml for more than 96% infants (>1.3 microg/ml for at least 70%), and IgG to non-7PCV serotypes was >0.35 microg/ml for more than 50% infants (including serotype 6A, but not 12F (17%) or 19A (44%).
CONCLUSION: 7PCV and 23PPV are immunogenic in this population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562052     DOI: 10.1016/j.vaccine.2008.05.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.

Authors:  Paul V Licciardi; Anne Balloch; Fiona M Russell; Robert L Burton; Jisheng Lin; Moon H Nahm; Edward K Mulholland; Mimi L K Tang
Journal:  J Allergy Clin Immunol       Date:  2012-02-02       Impact factor: 10.793

2.  Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial.

Authors:  Amanda Jane Leach; Edward Kim Mulholland; Mathu Santosham; Paul John Torzillo; Ngiare Joy Brown; Peter McIntyre; Heidi Smith-Vaughan; Sue Skull; Anne Balloch; Ross Andrews; Jonathan Carapetis; Joseph McDonnell; Vicki Krause; Peter Stanley Morris
Journal:  BMJ Open       Date:  2015-01-16       Impact factor: 2.692

3.  BIGDATA: A Protocol to Create and Extend a 25-Year Clinical Trial and Observational Data Asset to Address Key Knowledge Gaps in Otitis Media and Hearing Loss in Australian Aboriginal and Non-Aboriginal Children.

Authors:  Jemima Beissbarth; Heidi C Smith-Vaughan; Allen C Cheng; Peter S Morris; Amanda J Leach
Journal:  Front Pediatr       Date:  2022-04-14       Impact factor: 3.418

4.  Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001.

Authors:  Amanda J Leach; Peter S Morris; Gabrielle B McCallum; Cate A Wilson; Liz Stubbs; Jemima Beissbarth; Susan Jacups; Kim Hare; Heidi C Smith-Vaughan
Journal:  BMC Infect Dis       Date:  2009-08-04       Impact factor: 3.090

5.  Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination.

Authors:  Grant Austin Mackenzie; Jonathan Rhys Carapetis; Amanda Jane Leach; Peter Stanley Morris
Journal:  BMC Pediatr       Date:  2009-02-19       Impact factor: 2.125

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.